^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Skin Cancer

    Related cancers:
    1d
    NeoMatryx: Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab (clinicaltrials.gov)
    P2, N=135, Recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Libtayo (cemiplimab-rwlc)
    1d
    Tumor safety of biologic agents and targeted therapies in immune-mediated inflammatory arthritides. (PubMed, Front Immunol)
    Overall, most biologic therapies appear broadly reassuring with respect to overall malignancy, although non-melanoma skin cancer remains the most reproducible treatment-associated signal, particularly with tumor necrosis factor inhibitors and possibly abatacept. Rituximab retains a favorable profile in patients with prior lymphoproliferative disease, whereas IL-6 and IL-17/23 pathway inhibitors appear largely neutral or reassuring in currently available datasets...We further examine tumor-type-specific patterns, major modifiers of risk, and practical risk-stratified management strategies. The central clinical message is that malignancy safety in IMIA should be interpreted through an individualized framework that balances inflammatory control against oncologic vulnerability rather than through uniform class-based avoidance.
    Review • Journal
    |
    IL6 (Interleukin 6) • IL17A (Interleukin 17A)
    |
    Rituxan (rituximab) • Orencia (abatacept)
    2d
    IIT BLT: Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade (clinicaltrials.gov)
    P=N/A, N=12, Not yet recruiting, Weill Medical College of Cornell University
    New trial • Checkpoint inhibition
    5d
    Transcriptomic Profiling of Cutaneous Melanoma Metastases Treated With Microwave Ablation-Pilot Study. (PubMed, Clin Transl Sci)
    Compared with partial responders, complete responders showed enrichment of FABP4 and reduced expression of cancer markers. Microwave therapy produced local tumor responses and associated inflammatory transcriptomic changes in complete responders, supporting further clinical evaluation in cutaneous melanoma metastases.
    Journal
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • PRAME (Preferentially Expressed Antigen In Melanoma) • COL1A1 (Collagen Type I Alpha 1 Chain) • IL1A (Interleukin 1, alpha) • MLANA (Melan-A) • CXCL5 (Chemokine (C-X-C motif) ligand 5) • FABP4 (Fatty Acid Binding Protein 4) • S100B (S100 Calcium Binding Protein B)
    5d
    First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors. (PubMed, J Immunother Cancer)
    Lomvastomig had a tolerable and manageable safety profile at 2,100 mg Q2W. Clinical activity was limited in CPI-experienced patients with melanoma and NSCLC, while an encouraging signal was observed in CPI-naïve patients with ESCC.
    P1 data • Journal • First-in-human
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
    |
    lomvastomig (RG7769)
    5d
    Hereditary Cancer Genetic Testing for All? A Retrospective Analysis on Genetic Mutations Found in Individuals Not Meeting NCCN® Guidelines. (PubMed, Eur J Breast Health)
    These findings support the potential value of expanded or universal genetic testing strategies, particularly in populations with limited family history or those outside current clinical criteria.
    Retrospective data • Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NF1 (Neurofibromin 1) • BAP1 (BRCA1 Associated Protein 1) • PALB2 (Partner and localizer of BRCA2) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • SMAD4 (SMAD family member 4) • PMS2 (PMS1 protein homolog 2) • APC (APC Regulator Of WNT Signaling Pathway) • CDH1 (Cadherin 1) • CHEK2 (Checkpoint kinase 2) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • MBD4 (Methyl-CpG Binding Domain 4, DNA Glycosylase) • MSH3 (MutS Homolog 3) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • MUTYH (MutY homolog) • FLCN (Folliculin) • POT1 (Protection of telomeres 1) • MITF (Melanocyte Inducing Transcription Factor) • SDHD (Succinate Dehydrogenase Complex Subunit D) • HOXB13 (Homeobox B13) • LZTR1 (Leucine Zipper Like Transcription Regulator 1) • SDHA (Succinate Dehydrogenase Complex Flavoprotein Subunit A)
    |
    ATM mutation • CHEK2 mutation • BRIP1 mutation • BARD1 mutation
    |
    CancerNext-Expanded®
    6d
    FLARE: Family Lifestyles, Actions, and Risk Education Intervention: Version 2 (clinicaltrials.gov)
    P=N/A, N=752, Completed, University of Utah | Active, not recruiting --> Completed
    Trial completion
    6d
    Vitamin D Effects on Immune Microenvironment of Nonmelanoma Skin Cancer After Photodynamic Therapy (PDT) (clinicaltrials.gov)
    P=N/A, N=54, Recruiting, Case Comprehensive Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    6d
    THERMS: The Application of Infrared Thermography in the Prediction of Skin Healing in Surgery (clinicaltrials.gov)
    P=N/A, N=120, Recruiting, Universitaire Ziekenhuizen KU Leuven | Not yet recruiting --> Recruiting
    Enrollment open
    6d
    The first-in-human ENCIT01 trial comparing second- versus third-generation L1CAM-specific CAR T cells in patients with primary refractory or relapsed neuroblastoma. (PubMed, Clin Cancer Res)
    While feasible to manufacture in a heavily pretreated population, L1CAM may not be an appropriate target in neuroblastoma. Additional engineering strategies may be needed to prevent toxicity and provide durable anti-tumor effects.
    P1 data • Journal • First-in-human
    |
    L1CAM (L1 cell adhesion molecule)
    6d
    Therapy of melanoma : Current standards and future perspectives (PubMed, Pathologie (Heidelb))
    Multimodal treatment strategies have fundamentally improved the prognosis of melanoma. Therapy selection should be individualized based on molecular markers and disease stage. Future developments aim to integrate combination strategies, personalized immunotherapeutic approaches, and the overcoming of resistance mechanisms.
    Review • Journal • IO biomarker
    |
    LAG3 (Lymphocyte Activating 3)
    |
    BRAF mutation • BRAF V600
    |
    Nidlegy (darleukin/fibromun)
    7d
    Mel73: Evaluating a Decision Aid for Sentinel Lymph Node Biopsy in Intermediate-Risk Melanoma (clinicaltrials.gov)
    P=N/A, N=66, Not yet recruiting, University of Virginia
    New trial